{"id":"injectable-insulin","safety":{"commonSideEffects":[{"rate":"variable, dose-dependent","effect":"Hypoglycemia"},{"rate":"common","effect":"Weight gain"},{"rate":"5–10","effect":"Injection site reactions"},{"rate":"rare to uncommon","effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":{"setId":"e49f701d-c19f-4cb2-b63f-01a917b33abc","title":"INSULIN LISPRO PROTAMINE AND INSULIN LISPRO INJECTABLE SUSPENSION MIX75/25 KWIKPEN (INSULIN LISPRO) INJECTION, SUSPENSION [ELI LILLY AND COMPANY]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin is a peptide hormone that binds to insulin receptors on muscle, fat, and liver cells, promoting glucose transport into cells and conversion to glycogen or fat for energy storage and metabolism. This lowers blood glucose levels in patients with diabetes who cannot produce sufficient endogenous insulin (type 1 diabetes) or have impaired insulin secretion/action (type 2 diabetes).","oneSentence":"Injectable insulin replaces or supplements the body's own insulin to regulate blood glucose by facilitating cellular glucose uptake and storage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:13.835Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus (when oral agents are insufficient)"}]},"trialDetails":[{"nctId":"NCT02230137","phase":"NA","title":"Text Message for Adolescents With Poorly Controlled Type 1 Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Type 1 Diabetes","enrollment":92},{"nctId":"NCT02556840","phase":"NA","title":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-25","conditions":"Maturity-Onset Diabetes of the Young","enrollment":46},{"nctId":"NCT07037420","phase":"PHASE2","title":"ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-10-28","conditions":"Acromegaly","enrollment":60},{"nctId":"NCT07361874","phase":"NA","title":"IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-03-05","conditions":"Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's","enrollment":75},{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":"Obesity & Overweight, Mobility Disability, HOMA-IR","enrollment":200},{"nctId":"NCT07491133","phase":"NA","title":"Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2026-03","conditions":"Type 1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT04542148","phase":"PHASE2","title":"Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-10","conditions":"Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk","enrollment":120},{"nctId":"NCT07481500","phase":"NA","title":"Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","status":"NOT_YET_RECRUITING","sponsor":"Jakkrit Juhong","startDate":"2026-06","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":120},{"nctId":"NCT07471854","phase":"NA","title":"Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne Scars","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-01","conditions":"Acne Scars - Atrophic","enrollment":42},{"nctId":"NCT07423637","phase":"NA","title":"The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2026-04-01","conditions":"Type 1 Diabetes","enrollment":100},{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT06198725","phase":"NA","title":"Intervention for Children With Type 1 Diabetes Targeting Gut Microbes","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2024-01-08","conditions":"Type 1 Diabetes","enrollment":110},{"nctId":"NCT06762314","phase":"PHASE2","title":"Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-01-20","conditions":"Diabetes","enrollment":105},{"nctId":"NCT07137585","phase":"PHASE1","title":"A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-09-30","conditions":"Type 2 Diabetes Mellitus, Obesity, Overweight","enrollment":30},{"nctId":"NCT05258292","phase":"","title":"Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes","status":"RECRUITING","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2022-05-02","conditions":"Type1diabetes","enrollment":86},{"nctId":"NCT05539872","phase":"PHASE2, PHASE3","title":"Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2022-08-22","conditions":"Pharmacokinetics, Pharmacodynamics","enrollment":69},{"nctId":"NCT06747468","phase":"PHASE3","title":"Avexitide for Treatment of Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2025-04-29","conditions":"Post Bariatric Hypoglycemia","enrollment":75},{"nctId":"NCT06640478","phase":"NA","title":"A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2024-11-20","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT00743782","phase":"PHASE2","title":"Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2008-08-22","conditions":"Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1","enrollment":21},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06403761","phase":"PHASE1","title":"Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-06","conditions":"Diabetes Mellitus, Type 2","enrollment":158},{"nctId":"NCT05985135","phase":"NA","title":"Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-06-01","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT07348809","phase":"NA","title":"The Effects Of Virtual Reality and Stress Ball Application on Pain, Anxiety Levels and Injection Satisfaction in During Insulin Injection in Geriatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tarsus University","startDate":"2024-11-01","conditions":"Diabete Type 2, Virtual Reality, Stress Ball","enrollment":90},{"nctId":"NCT05653518","phase":"NA","title":"Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2023-09-09","conditions":"Type 1 Diabetes","enrollment":40},{"nctId":"NCT07427134","phase":"NA","title":"Pediatric Insulin Plan Calculator for T1DM Management","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2026-03-01","conditions":"Type 1 Diabetes Mellitus, Type 1 Diabetes Mellitus (T1DM), T1DM","enrollment":440},{"nctId":"NCT05018585","phase":"PHASE3","title":"A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diamyd Medical AB","startDate":"2022-05-19","conditions":"Type 1 Diabetes Mellitus","enrollment":330},{"nctId":"NCT06449677","phase":"PHASE3","title":"Bionic Pancreas in CFRD","status":"RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2024-09-24","conditions":"Cystic Fibrosis-related Diabetes","enrollment":150},{"nctId":"NCT07422532","phase":"NA","title":"A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing Haemodialysis","status":"NOT_YET_RECRUITING","sponsor":"Imperial College London","startDate":"2026-04-01","conditions":"Type 2 Diabetes, Chronic Kidney Disease 5D","enrollment":84},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT06369649","phase":"NA","title":"Coolsense and Buzzy Use on Pain Score and Anxiety Level During Insulin Injection Application","status":"COMPLETED","sponsor":"Ankara Yildirim Beyazıt University","startDate":"2023-07-01","conditions":"Injection Fear, Injection Site Coldness, Pain","enrollment":90},{"nctId":"NCT05562492","phase":"NA","title":"Closed-loop for People Living With Cystic Fibrosis Related Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2023-04-12","conditions":"Cystic Fibrosis-related Diabetes","enrollment":128},{"nctId":"NCT06140147","phase":"NA","title":"Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients","status":"RECRUITING","sponsor":"Region Skane","startDate":"2023-11-27","conditions":"Septic Shock","enrollment":1850},{"nctId":"NCT06111586","phase":"PHASE2","title":"FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-12-11","conditions":"Type 1 Diabetes Mellitus","enrollment":192},{"nctId":"NCT07287943","phase":"NA","title":"To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.","status":"RECRUITING","sponsor":"Viral N. Shah","startDate":"2026-02-09","conditions":"Type 1 Diabetes, Gastroparesis Due to Diabetes Mellitus Type I","enrollment":34},{"nctId":"NCT07059091","phase":"PHASE2","title":"Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-02-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Allergies","enrollment":334},{"nctId":"NCT06024928","phase":"NA","title":"Automated Insulin Delivery (AID) for Basal Insulin Titration in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2024-06-18","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT07087340","phase":"NA","title":"Early Feasibility Evaluation of the UniBE Hybrid Closed-loop Insulin Delivery System in Type 1 Diabetes: UBLoop-Genesis","status":"RECRUITING","sponsor":"University of Bern","startDate":"2026-01-21","conditions":"Type-1-Diabetes","enrollment":6},{"nctId":"NCT06782568","phase":"NA","title":"Avoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2026-01-01","conditions":"Type 1 Diabetes (T1D), Type 2 Diabetes, Insulin Requiring","enrollment":50},{"nctId":"NCT06330194","phase":"NA","title":"Next Generation Advanced Insulin Delivery System in Adults With Diabetes and Advanced Renal Disease","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2024-04-18","conditions":"Dialysis, Chronic Kidney Disease, Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT07167693","phase":"PHASE1, PHASE2","title":"Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes","status":"RECRUITING","sponsor":"David K Carroll","startDate":"2025-12-19","conditions":"Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes","enrollment":60},{"nctId":"NCT07407881","phase":"NA","title":"Shot Blocker and Manual Pressure Application","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2025-07-25","conditions":"Injection Pain Prevention","enrollment":108},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT06986603","phase":"PHASE4","title":"Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joslin Diabetes Center","startDate":"2024-11-26","conditions":"Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery","enrollment":28},{"nctId":"NCT00903110","phase":"","title":"Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).","status":"RECRUITING","sponsor":"Esteve Pharmaceuticals, S.A.","startDate":"2008-12-09","conditions":"IGF1 Deficiency","enrollment":500},{"nctId":"NCT07388420","phase":"NA","title":"Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2026-01-02","conditions":"Hypertriglyceridemia Induced Acute Pancreatitis","enrollment":40},{"nctId":"NCT07387003","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-03-20","conditions":"Type 2 Diabetes (T2DM)","enrollment":300},{"nctId":"NCT07375875","phase":"NA","title":"Strategies to Minimize the Risk for Insulin Induced Hypertrophy and Its Related Consequences","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2025-05-15","conditions":"Insulin Dependent Diabetes Mellitus","enrollment":170},{"nctId":"NCT07376200","phase":"PHASE1","title":"Single-ascending Dose Study of HEC-151 Injection","status":"NOT_YET_RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2026-03-11","conditions":"Healthy Adult Male","enrollment":81},{"nctId":"NCT07303556","phase":"NA","title":"Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nazarbayev University","startDate":"2024-12-18","conditions":"Heart Failure, Diabete Type 2, Arterial Hypertension","enrollment":120},{"nctId":"NCT06881264","phase":"PHASE3","title":"A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-04-30","conditions":"Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs","enrollment":401},{"nctId":"NCT07370922","phase":"PHASE2","title":"Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-11-22","conditions":"Transfusion Dependent Beta Thalassemia","enrollment":80},{"nctId":"NCT07088497","phase":"","title":"Cmate Blood Glucose Analyzer: Clinical Comparison Study of Fasting Blood Glucose Levels in the Morning","status":"COMPLETED","sponsor":"Revlis Biotech Company Limited","startDate":"2025-07-21","conditions":"Glucose, Diabetes","enrollment":40},{"nctId":"NCT07364669","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Pisa S.A. de C.V.","startDate":"2024-10-24","conditions":"Healthy Subjects","enrollment":40},{"nctId":"NCT01239550","phase":"NA","title":"Insulin Detemir in Obesity Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2011-04","conditions":"Diabetes, Obesity","enrollment":240},{"nctId":"NCT06716424","phase":"PHASE4","title":"A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-01-06","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT05669547","phase":"NA","title":"Dual Hormone Closed Loop in Type 1 Diabetes","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2023-10-03","conditions":"Diabetes Mellitus, Type 1, Diabetes type1, Diabetes","enrollment":243},{"nctId":"NCT07348432","phase":"","title":"The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes","status":"RECRUITING","sponsor":"McGill University","startDate":"2024-07-29","conditions":"Insulin Dependent Diabetes Mellitus, Feeding and Eating Disorders, Eating Behavior","enrollment":106},{"nctId":"NCT06904846","phase":"NA","title":"To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period","status":"ENROLLING_BY_INVITATION","sponsor":"Sinocare","startDate":"2025-04-23","conditions":"Diabetes Mellitus, Continuous Glucose Monitoring System","enrollment":70},{"nctId":"NCT06871761","phase":"PHASE3","title":"A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-05-08","conditions":"Adult Patients With Type 2 Diabetes","enrollment":393},{"nctId":"NCT07076199","phase":"PHASE3","title":"A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-11","conditions":"Diabetes Mellitus, Type 1","enrollment":877},{"nctId":"NCT07112339","phase":"PHASE4","title":"A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-15","conditions":"Diabetes Mellitus, Type 2","enrollment":586},{"nctId":"NCT03746431","phase":"PHASE1","title":"A Phase 1 Study of [225Ac]-FPI-1434 Injection","status":"TERMINATED","sponsor":"Fusion Pharmaceuticals Inc.","startDate":"2019-01-17","conditions":"Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer","enrollment":78},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT07317856","phase":"NA","title":"Efficacy of Microneedling With Hyaluronic Acid Injection for Gingival Augmentation in Thin Gingival Phenotype","status":"NOT_YET_RECRUITING","sponsor":"University of Baghdad","startDate":"2026-01","conditions":"Thin Gingival Biotype","enrollment":20},{"nctId":"NCT07316582","phase":"PHASE4","title":"Melatonin Loaded in Injectable Platelet-Rich Fibrin in the Management Periodontitis","status":"ENROLLING_BY_INVITATION","sponsor":"Al-Azhar University","startDate":"2025-11-01","conditions":"Periodontitis Stage II","enrollment":60},{"nctId":"NCT07311759","phase":"PHASE3","title":"Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2024-08-17","conditions":"Chronic Paronychia","enrollment":21},{"nctId":"NCT07307235","phase":"PHASE4","title":"Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-15","conditions":"Type 2 Diabetes","enrollment":1316},{"nctId":"NCT05834868","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-05-06","conditions":"Type 2 Diabetes","enrollment":1040},{"nctId":"NCT05616273","phase":"","title":"Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Exeter","startDate":"2023-05-03","conditions":"Type 1 Diabetes, Hypoglycemia","enrollment":62},{"nctId":"NCT06236607","phase":"NA","title":"Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Boston Medical Center","startDate":"2025-02-27","conditions":"Diabetes Mellitus, Type 1, Diabetes Complications","enrollment":140},{"nctId":"NCT06812325","phase":"PHASE3","title":"A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viridian Therapeutics, Inc.","startDate":"2025-02-03","conditions":"Thyroid Eye Disease (TED)","enrollment":321},{"nctId":"NCT07284511","phase":"PHASE2, PHASE3","title":"A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar","status":"NOT_YET_RECRUITING","sponsor":"Melissa-Rosina Pasqua","startDate":"2026-01-05","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D","enrollment":105},{"nctId":"NCT07282054","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-04-13","conditions":"Type 1 Diabetes","enrollment":550},{"nctId":"NCT04770532","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-05","conditions":"Diabetes Mellitus, Type 2","enrollment":526},{"nctId":"NCT02081326","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2015-06","conditions":"Diabetes Mellitus, Type One, Diabetes Mellitus, Type I, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05180591","phase":"PHASE2","title":"Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-03-22","conditions":"Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05866536","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-05-04","conditions":"Diabetes Mellitus, Type 1 Diabetes, Diabetes type1","enrollment":100},{"nctId":"NCT04510506","phase":"NA","title":"Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2020-11-19","conditions":"Type 1 Diabetes","enrollment":42},{"nctId":"NCT07090824","phase":"PHASE1","title":"Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-10-28","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT04460885","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-25","conditions":"Diabetes Mellitus, Type 2","enrollment":984},{"nctId":"NCT04848480","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-30","conditions":"Diabetes Mellitus, Type 1","enrollment":582},{"nctId":"NCT04698018","phase":"PHASE1","title":"A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT04880850","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-14","conditions":"Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT07052292","phase":"","title":"User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-07-01","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":125},{"nctId":"NCT04588259","phase":"PHASE3","title":"Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT05417841","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2023-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":218},{"nctId":"NCT02546401","phase":"PHASE3","title":"Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2015-09","conditions":"Diabetes Type 1","enrollment":22},{"nctId":"NCT05013229","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":679},{"nctId":"NCT07259564","phase":"PHASE2","title":"A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-12-19","conditions":"Adult Growth Hormone Deficiency (AGHD)","enrollment":120},{"nctId":"NCT07255807","phase":"NA","title":"Defining the Human Insulin Resistance Molecular Network; SIGNATURE","status":"NOT_YET_RECRUITING","sponsor":"University of Copenhagen","startDate":"2025-12-01","conditions":"Metabolic Health, Insulin Sensitivity/Resistance","enrollment":80},{"nctId":"NCT06323161","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-26","conditions":"Type 2 Diabetes","enrollment":274},{"nctId":"NCT07193147","phase":"PHASE1","title":"Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-10-20","conditions":"Diabetes","enrollment":36},{"nctId":"NCT07241702","phase":"","title":"EFFECT OF HYBRID CLOSED-LOOP SYSTEMS ON CARDIOVASCULAR MARKERS IN TYPE 1 DIABETES.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Attikon Hospital","startDate":"2019-09-01","conditions":"Type 1 Diabetes","enrollment":100},{"nctId":"NCT07239700","phase":"NA","title":"Buzzy and TickleFlex in Reducing Insulin Injection Pain and Fear","status":"ENROLLING_BY_INVITATION","sponsor":"Hakkari Universitesi","startDate":"2025-06-06","conditions":"Diabete Type 1, Diabetes in Children","enrollment":90},{"nctId":"NCT06646107","phase":"","title":"Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There a Difference","status":"RECRUITING","sponsor":"Attikon Hospital","startDate":"2025-03-01","conditions":"Type1diabetes","enrollment":240},{"nctId":"NCT07018453","phase":"PHASE2","title":"A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-07-16","conditions":"Type 2 Diabetes Mellitus","enrollment":173},{"nctId":"NCT06418880","phase":"PHASE3","title":"Automated Insulin Delivery for Inpatients With Dysglycemia","status":"COMPLETED","sponsor":"Emory University","startDate":"2025-01-22","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":130},{"nctId":"NCT04443153","phase":"NA","title":"Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2020-09-04","conditions":"Diabetes Mellitus, Type 1","enrollment":88},{"nctId":"NCT06411548","phase":"NA","title":"InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2025-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":7}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"CHEST DISCOMFORT"},{"count":2,"reaction":"CHEST PAIN"},{"count":2,"reaction":"CORONARY ARTERY STENOSIS"},{"count":2,"reaction":"MYOCARDIAL INFARCTION"},{"count":1,"reaction":"APPARENT DEATH"},{"count":1,"reaction":"BLOOD PRESSURE ABNORMAL"},{"count":1,"reaction":"CARDIAC FAILURE CONGESTIVE"},{"count":1,"reaction":"CARDIOMYOPATHY"},{"count":1,"reaction":"DIABETIC KETOACIDOSIS"},{"count":1,"reaction":"DRUG INEFFECTIVE"}],"_approvalHistory":[],"publicationCount":108,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Injectable insulin","genericName":"Injectable insulin","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Injectable insulin replaces or supplements the body's own insulin to regulate blood glucose by facilitating cellular glucose uptake and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}